Frédéric Baron, Stefan Suciu, Sergio Amadori, Petra Muus, Heinz Zwierzina, Claudio Denzlinger, Michel Delforge, Antoine Thyss, Dominik Selleslag, Karel Indrak, Gert Ossenkoppele, Theo de Witte. Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. haematol [Internet]. 2012Apr.5 [cited 2024Apr.26];97(4):529-33. Available from: https://haematologica.org/article/view/6266